[HTML][HTML] Broadly neutralizing antibodies against COVID-19
The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …
A combination of receptor-binding domain and N-terminal domain neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
D Haslwanter, ME Dieterle, AZ Wec, CM O'brien… - Mbio, 2021 - Am Soc Microbiol
Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …
[HTML][HTML] Neutralizing antibody: a savior in the Covid-19 disease
SL Gupta, RK Jaiswal - Molecular biology reports, 2022 - Springer
Coronavirus outbreak was declared a pandemic by World Health Organization (WHO) in
March 2020. The pandemic has led to a devastating loss of life. It has shown us how …
March 2020. The pandemic has led to a devastating loss of life. It has shown us how …
[PDF][PDF] Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …
[HTML][HTML] Neutralizing antibodies targeting SARS-CoV-2 spike protein
S Xiaojie, L Yu, Y Guang, Q Min - Stem cell research, 2021 - Elsevier
SARS-CoV-2 causing the worldwide pandemic has changed people's life in multiple aspects
dramatically since it's first identified in Wuhan, China at the end of 2019. While the numbers …
dramatically since it's first identified in Wuhan, China at the end of 2019. While the numbers …
Monoclonal antibodies for the treatment of COVID-19 patients: an umbrella to overcome the storm?
SM Pinna, T Lupia, S Scabini, D Vita… - International …, 2021 - Elsevier
The world is facing up the most considerable vaccination effort in history to end the
Coronavirus disease 2019 (COVID-19) pandemic. Several monoclonal antibodies (mAbs) …
Coronavirus disease 2019 (COVID-19) pandemic. Several monoclonal antibodies (mAbs) …
[PDF][PDF] Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
T Noy-Porat, A Mechaly, Y Levy, E Makdasi, R Alcalay… - Iscience, 2021 - cell.com
Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …
[PDF][PDF] Tackling COVID-19 with neutralizing monoclonal antibodies
Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
[HTML][HTML] SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …
and are especially important in high-risk individuals where vaccination is not an option …
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …